Prognostic value of the number of circulating tumor cells in patients with metastatic non-small cell lung cancer

Arthur B. Volovetsky; Victoria A. Novikova; Anastasia Boloban; Aleksej S. Rzhevskiy; Alina Kapitannikova; Elena G. Ovchinnikova; Tatjana P. Klejmentjeva; Vladislav A. Grishin; Yana Pigareva; Andrei V. Zvyagin; Majid Ebrahimi Warkiani; Anna V. Maslennikova

doi:10.3390/mi16040470

Prognostic value of the number of circulating tumor cells in patients with metastatic non-small cell lung cancer

Arthur B. Volovetsky, Victoria A. Novikova, Anastasia Boloban, Aleksej S. Rzhevskiy, Alina Kapitannikova, Elena G. Ovchinnikova, Tatjana P. Klejmentjeva, Vladislav A. Grishin, Yana Pigareva, Andrei V. Zvyagin, Majid Ebrahimi Warkiani, Anna V. Maslennikova^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given the limitations of traditional biopsy and histopathology. This study aimed to isolate, characterize, and analyze CTC dynamics in the peripheral blood of 30 patients with metastatic lung cancer to develop criteria for treatment response and prognosis. We detected CTCs before the start of the treatment and monitored changes during treatment, correlating these with responses evaluated by standard imaging methods. A decrease in the CTCs in the course of the therapy was linked to a favorable tumor response, while the stable CTC counts indicated a lack of response and poor survival prognosis. The OS of patients was analyzed and compared with the initial number of CTCs in peripheral blood samples. The significant reductions in median OS were evident in patients with >3 total CTCs at baseline compared to those with ≤3 total CTCs (median survival 26 months, n = 10, vs. median survival 8 months, n = 19, respectively with HR = 2.6, 95% CI 1.07 to 6.4).

Original language	English
Article number	470
Pages (from-to)	1-16
Number of pages	16
Journal	Micromachines
Volume	16
Issue number	4
DOIs	https://doi.org/10.3390/mi16040470
Publication status	Published - Apr 2025

Bibliographical note

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

chemotherapy
circulating tumor cells
CTCs detection
metastases
microfluidic
non-small cell lung cancer
targeted therapy

Access to Document

10.3390/mi16040470Licence: CC BY

Publisher version (open access)Final published version, 4.94 MBLicence: CC BY

Cite this

Volovetsky, A. B., Novikova, V. A., Boloban, A., Rzhevskiy, A. S., Kapitannikova, A., Ovchinnikova, E. G., Klejmentjeva, T. P., Grishin, V. A., Pigareva, Y., Zvyagin, A. V., Ebrahimi Warkiani, M., & Maslennikova, A. V. (2025). Prognostic value of the number of circulating tumor cells in patients with metastatic non-small cell lung cancer. Micromachines, 16(4), 1-16. Article 470. https://doi.org/10.3390/mi16040470

@article{cda1b933ecb749e9b2caaee086fe5d02,

title = "Prognostic value of the number of circulating tumor cells in patients with metastatic non-small cell lung cancer",

abstract = "Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given the limitations of traditional biopsy and histopathology. This study aimed to isolate, characterize, and analyze CTC dynamics in the peripheral blood of 30 patients with metastatic lung cancer to develop criteria for treatment response and prognosis. We detected CTCs before the start of the treatment and monitored changes during treatment, correlating these with responses evaluated by standard imaging methods. A decrease in the CTCs in the course of the therapy was linked to a favorable tumor response, while the stable CTC counts indicated a lack of response and poor survival prognosis. The OS of patients was analyzed and compared with the initial number of CTCs in peripheral blood samples. The significant reductions in median OS were evident in patients with >3 total CTCs at baseline compared to those with ≤3 total CTCs (median survival 26 months, n = 10, vs. median survival 8 months, n = 19, respectively with HR = 2.6, 95\% CI 1.07 to 6.4).",

keywords = "chemotherapy, circulating tumor cells, CTCs detection, metastases, microfluidic, non-small cell lung cancer, targeted therapy",

author = "Volovetsky, \{Arthur B.\} and Novikova, \{Victoria A.\} and Anastasia Boloban and Rzhevskiy, \{Aleksej S.\} and Alina Kapitannikova and Ovchinnikova, \{Elena G.\} and Klejmentjeva, \{Tatjana P.\} and Grishin, \{Vladislav A.\} and Yana Pigareva and Zvyagin, \{Andrei V.\} and \{Ebrahimi Warkiani\}, Majid and Maslennikova, \{Anna V.\}",

note = "{\textcopyright} 2025 by the authors. Licensee MDPI, Basel, Switzerland. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2025",

month = apr,

doi = "10.3390/mi16040470",

language = "English",

volume = "16",

pages = "1--16",

journal = "Micromachines",

issn = "2072-666X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

Volovetsky, AB, Novikova, VA, Boloban, A, Rzhevskiy, AS, Kapitannikova, A, Ovchinnikova, EG, Klejmentjeva, TP, Grishin, VA, Pigareva, Y, Zvyagin, AV, Ebrahimi Warkiani, M & Maslennikova, AV 2025, 'Prognostic value of the number of circulating tumor cells in patients with metastatic non-small cell lung cancer', Micromachines, vol. 16, no. 4, 470, pp. 1-16. https://doi.org/10.3390/mi16040470

TY - JOUR

T1 - Prognostic value of the number of circulating tumor cells in patients with metastatic non-small cell lung cancer

AU - Volovetsky, Arthur B.

AU - Novikova, Victoria A.

AU - Boloban, Anastasia

AU - Rzhevskiy, Aleksej S.

AU - Kapitannikova, Alina

AU - Ovchinnikova, Elena G.

AU - Klejmentjeva, Tatjana P.

AU - Grishin, Vladislav A.

AU - Pigareva, Yana

AU - Zvyagin, Andrei V.

AU - Ebrahimi Warkiani, Majid

AU - Maslennikova, Anna V.

N1 - © 2025 by the authors. Licensee MDPI, Basel, Switzerland. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2025/4

Y1 - 2025/4

N2 - Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given the limitations of traditional biopsy and histopathology. This study aimed to isolate, characterize, and analyze CTC dynamics in the peripheral blood of 30 patients with metastatic lung cancer to develop criteria for treatment response and prognosis. We detected CTCs before the start of the treatment and monitored changes during treatment, correlating these with responses evaluated by standard imaging methods. A decrease in the CTCs in the course of the therapy was linked to a favorable tumor response, while the stable CTC counts indicated a lack of response and poor survival prognosis. The OS of patients was analyzed and compared with the initial number of CTCs in peripheral blood samples. The significant reductions in median OS were evident in patients with >3 total CTCs at baseline compared to those with ≤3 total CTCs (median survival 26 months, n = 10, vs. median survival 8 months, n = 19, respectively with HR = 2.6, 95% CI 1.07 to 6.4).

AB - Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given the limitations of traditional biopsy and histopathology. This study aimed to isolate, characterize, and analyze CTC dynamics in the peripheral blood of 30 patients with metastatic lung cancer to develop criteria for treatment response and prognosis. We detected CTCs before the start of the treatment and monitored changes during treatment, correlating these with responses evaluated by standard imaging methods. A decrease in the CTCs in the course of the therapy was linked to a favorable tumor response, while the stable CTC counts indicated a lack of response and poor survival prognosis. The OS of patients was analyzed and compared with the initial number of CTCs in peripheral blood samples. The significant reductions in median OS were evident in patients with >3 total CTCs at baseline compared to those with ≤3 total CTCs (median survival 26 months, n = 10, vs. median survival 8 months, n = 19, respectively with HR = 2.6, 95% CI 1.07 to 6.4).

KW - chemotherapy

KW - circulating tumor cells

KW - CTCs detection

KW - metastases

KW - microfluidic

KW - non-small cell lung cancer

KW - targeted therapy

UR - https://www.scopus.com/pages/publications/105003685115

U2 - 10.3390/mi16040470

DO - 10.3390/mi16040470

M3 - Article

C2 - 40283345

AN - SCOPUS:105003685115

SN - 2072-666X

VL - 16

SP - 1

EP - 16

JO - Micromachines

JF - Micromachines

IS - 4

M1 - 470

ER -

Prognostic value of the number of circulating tumor cells in patients with metastatic non-small cell lung cancer

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this